Historia
1 Mar 2005
GlaxoSmithKline, AstraZeneca, Merck, Pfizer & other firms join UK govt. in committing to increased access to essential medicines for poorest countries, including via differential pricing
Ver todas las etiquetas
Ver todas las etiquetas
Abbott Laboratories
AstraZeneca
Amgen
Bristol-Myers Squibb
Chiron
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck
Merck Sharp & Dohme (part of Merck)
Novartis
Pfizer
Procter & Gamble
Roche
Ranbaxy Laboratories
Schering-Plough
Shire
Tibotec (part of Johnson & Johnson)
Wyeth (part of Pfizer)
Janssen Pharmaceutica (part of Johnson & Johnson)
Acceso a medicinas
Enfermedades
Propiedad intelectual
Reputación
Lineamientos OCDE
Lineamientos preparados por gobiernos
G7
OMS
Unión Europea y Parlamento Europeo
Banco Mundial
OMC
Personal Health
Trade
Company Reporting
Company Support for Initiatives Promoting Development, Economic and Social Rights